Cibus, Inc. announced steps to implement a more streamlined business focus, prioritizing its nearest-term revenue opportunities. This strategic realignment centers on advancing herbicide tolerance traits in Rice and partner-funded biofragrance products and sustainable ingredients.
The company expects these initiatives to reduce its annual net cash usage to approximately $30 million by 2026. This move is aimed at optimizing the company's cost structure and accelerating its transformation into a commercial-stage gene editing company.
Cibus stated it is well-situated to pursue partner funding to support its advanced productivity trait portfolio. This focused approach is critical for managing liquidity and achieving sustainable growth as the company moves towards generating meaningful revenue.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.